![](https://canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBcUFDIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--b4ffecd4a72ec699631b9b9b21658a38bc670286/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/rallybio.png)
Rallybio
Rallybio identifies and accelerates the development of transformative breakthrough therapies for patients with severe and rare disorders.
Website
rallybio.comPartner
Tim ShannonInvestment
Series A
Rallybio identifies and accelerates the development of transformative breakthrough therapies for patients with severe and rare disorders.
Series A